-+ 0.00%
-+ 0.00%
-+ 0.00%

ARS Pharma Q2 FY26 net loss widens to $62.34 million; revenue rises 114.11% to $33.66 million

PUBT·08/13/2026 20:02:30
Listen to the news
ARS Pharma Q2 FY26 net loss widens to $62.34 million; revenue rises 114.11% to $33.66 million
  • ARS Pharmaceuticals posted Q2 2026 revenue of USD 33.7 million, up 114.15% from a year earlier, driven by neffy net product revenue.
  • Net loss widened to USD 62.3 million, or USD 0.63 per share, versus a year-earlier loss of USD 44.9 million.
  • neffy net product revenue rose to USD 26.2 million, while total U.S. epinephrine market share for Type 1 allergies doubled to 5%.
  • Field-targeted account share climbed 4 percentage points to 8%, with more than 16,000 unique prescribers in the quarter.
  • Second-half SG&A and R&D expenses are guided at USD 114 million–USD 126 million; cash flow breakeven targeted by end-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809889) on August 13, 2026, and is solely responsible for the information contained therein.